Catalent Pharma Solutions, Inc. and ALK-Abello A/S have signed an agreement that will expand Zydis production capacity dedicated to ALK-Abello’s immunotherapy products. Under the agreement, ALK-Abello will fund a new production line for current and future tablet-based allergy products, which will be based at Catalent’s Swindon, UK facility. Commercial production on the new line is expected to begin in 2010. ALK-Abello has launched Grazax, a tablet-based vaccine against grass po...